These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. N-Phosphonomethyl dipeptides and their phosphonate prodrugs, a new generation of neutral endopeptidase (NEP, EC 3.4.24.11) inhibitors. De Lombaert S; Erion MD; Tan J; Blanchard L; el-Chehabi L; Ghai RD; Sakane Y; Berry C; Trapani AJ J Med Chem; 1994 Feb; 37(4):498-511. PubMed ID: 8120868 [TBL] [Abstract][Full Text] [Related]
84. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Jeng AY Curr Opin Investig Drugs; 2003 Sep; 4(9):1076-81. PubMed ID: 14582451 [TBL] [Abstract][Full Text] [Related]
85. Effect of a highly selective endothelin-converting enzyme inhibitor on cardiac remodeling in rats after myocardial infarction. Martin P; Tzanidis A; Stein-Oakley A; Krum H J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S367-70. PubMed ID: 11078422 [TBL] [Abstract][Full Text] [Related]
86. Altered expression of enzymes regulating the activity of endothelin-1 in the lower segment of the human amnion during labor. Kotani T; Iwase A; Tsuda H; Mano Y; Yamamoto E; Nakano T; Hasegawa Y; Li H; Sumigama S; Itakura A; Kikkawa F Biol Reprod; 2013 Sep; 89(3):52. PubMed ID: 23863409 [TBL] [Abstract][Full Text] [Related]
87. Endothelin-1 (1-31) is an intermediate in the production of endothelin-1 after big endothelin-1 administration in vivo. Fecteau MH; Honoré JC; Plante M; Labonté J; Rae GA; D'Orléans-Juste P Hypertension; 2005 Jul; 46(1):87-92. PubMed ID: 15956117 [TBL] [Abstract][Full Text] [Related]
88. Anti-peptide antibodies specific to rat endothelin-converting enzyme-1 isoforms reveal isoform localisation and expression. Brown CD; Barnes K; Turner AJ FEBS Lett; 1998 Mar; 424(3):183-7. PubMed ID: 9539147 [TBL] [Abstract][Full Text] [Related]
89. WS75624 A and B, new endothelin converting enzyme inhibitors isolated from Saccharothrix sp. No. 75624. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activities. Tsurumi Y; Ueda H; Hayashi K; Takase S; Nishikawa M; Kiyoto S; Okuhara M J Antibiot (Tokyo); 1995 Oct; 48(10):1066-72. PubMed ID: 7490208 [TBL] [Abstract][Full Text] [Related]
90. Characterization of PgPepO, a bacterial homologue of endothelin-converting enzyme-1. Carson JA; Ansai T; Awano S; Yu W; Takehara T; Turner AJ Clin Sci (Lond); 2002 Aug; 103 Suppl 48():90S-93S. PubMed ID: 12193062 [TBL] [Abstract][Full Text] [Related]
91. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH. Fahnoe DC; Knapp J; Johnson GD; Ahn K J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S22-5. PubMed ID: 11078325 [TBL] [Abstract][Full Text] [Related]
92. Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1. Firooznia F; Gude C; Chan K; Tan J; Fink CA; Savage P; Beil ME; Bruseo CW; Trapani AJ; Jeng AY Bioorg Med Chem Lett; 2002 Nov; 12(21):3059-62. PubMed ID: 12372501 [TBL] [Abstract][Full Text] [Related]
93. Rat endothelin-converting enzyme-1 forms a dimer through Cys412 with a similar catalytic mechanism and a distinct substrate binding mechanism compared with neutral endopeptidase-24.11. Shimada K; Takahashi M; Turner AJ; Tanzawa K Biochem J; 1996 May; 315 ( Pt 3)(Pt 3):863-7. PubMed ID: 8645169 [TBL] [Abstract][Full Text] [Related]
94. Homology modeling and site-directed mutagenesis to identify selective inhibitors of endothelin-converting enzyme-2. Gagnidze K; Sachchidanand ; Rozenfeld R; Mezei M; Zhou MM; Devi LA J Med Chem; 2008 Jun; 51(12):3378-87. PubMed ID: 18507370 [TBL] [Abstract][Full Text] [Related]
95. Endothelin Converting Enzyme-1 phosphorylation and trafficking. Kuruppu S; Smith AI FEBS Lett; 2012 Jul; 586(16):2212-7. PubMed ID: 22728136 [TBL] [Abstract][Full Text] [Related]
96. Targeting ACE and ECE with dual acting inhibitors. Hanessian S; Guesné S; Riber L; Marin J; Benoist A; Mennecier P; Rupin A; Verbeuren TJ; De Nanteuil G Bioorg Med Chem Lett; 2008 Feb; 18(3):1058-62. PubMed ID: 18160283 [TBL] [Abstract][Full Text] [Related]
97. Molecular modelling and site-directed mutagenesis of the active site of endothelin-converting enzyme. Sansom CE; Hoang MV; Turner AJ Protein Eng; 1998 Dec; 11(12):1235-41. PubMed ID: 9930673 [TBL] [Abstract][Full Text] [Related]
98. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. Daull P; Jeng AY; Battistini B J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751 [TBL] [Abstract][Full Text] [Related]
99. Endothelin and subarachnoid hemorrhage-induced cerebral vasospasm: pathogenesis and treatment. Lin CL; Jeng AY; Howng SL; Kwan AL Curr Med Chem; 2004 Jul; 11(13):1779-91. PubMed ID: 15279581 [TBL] [Abstract][Full Text] [Related]
100. Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle. Bihovsky R; Levinson BL; Loewi RC; Erhardt PW; Polokoff MA J Med Chem; 1995 Jun; 38(12):2119-29. PubMed ID: 7783143 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]